Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Twinfilin-2 (Twinfilin actin-binding protein 2) (TWF2)
- Target
- TWF2
- Molecular classification
- Actin-binding protein, Cytoskeleton regulator, Other
01
Overview
Twinfilin-2 is an actin-binding cytoskeletal protein comprised of two ADF/cofilin-like domains that regulate actin dynamics in eukaryotic cells. It binds actin monomers, inhibits actin polymerization, and in some cases can sever actin filaments, promoting rapid cytoskeletal turnover. Twinfilin-2 interacts with capping protein, which modulates its localization and activity within cells. It plays roles in cellular morphological regulation, migration, and possibly disease processes involving cytoskeletal changes. The current Ensembl annotation incorrectly lists twinfilin-2 in conjunction with toll-like receptor 9, which is not biochemically or genetically accurate.
- Other names
- Twinfilin-2TWF2PTK9L (previous)Twinfilin, actin-binding protein, homolog 2 (Drosophila)AC097637.1 (database ID)H0Y858H7C5I2 (UniProtKB identifiers)
02
Mechanism of action
Drugs targeting actin dynamics could theoretically alter TWF2 function through indirect effects on actin monomer sequestration, polymerization, and severing. No direct mechanism-of-action drugs described in literature.
03
Biological functions
Actin monomer bindingInhibition of actin polymerizationActin filament severing (especially in yeast and under certain conditions)Regulation of actin cytoskeleton organizationInteraction with capping protein for subcellular localizationPossible role in endocytosis and cell morphological processes
04
Disease associations
Cancer (possible role in cell migration/metastasis via cytoskeleton modulation, but not established as a major oncogene)Mpox (database association, not well-defined)Retinitis Pigmentosa 2 (database association)Other cytoskeletal and morphogenesis disorders (inferred from function)
05
Safety considerations
Cytoskeletal targeting may lead to broad cellular effects, such as impaired cell migration, proliferation, or unwanted cytotoxicity, but no drug-specific safety issues for TWF2 alone are noted.
06
Interacting drugs
None specifically recognized as of now. Target is not a direct pharmacological target, but actin modulators may impact function; no approved drugs identified in major databases.
07
Biomarkers
None established for patient selection or efficacy monitoring.
Beyond the preview
Go deeper on Twinfilin-2 (Twinfilin actin-binding protein 2) (TWF2).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Twinfilin-2 (Twinfilin actin-binding protein 2) (TWF2).